Download App
Current Complaints | Help Center| Subscribe
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Haleos Labs Ltd (HALEOSLABS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 540679 NSE: HALEOSLABS Pharmaceuticals & Drugs | Small Cap | Haleos Labs Share Price

₹1,535.15 -14.85 (-0.96%)

As on 16-Oct'26 16:59

Haleos Labs Ltd (HALEOSLABS)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 540679 NSE: HALEOSLABS Pharmaceuticals & Drugs | Small Cap | Haleos Labs Share Price

₹1,535.15 -14.85 (-0.96%)

As on 16-Oct'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹464 Cr.
Current Price
₹1,535.2
52-Week Low / High
₹1,101 / 1,778
TTM EPS
₹52.3
TTM Sales
₹324 Cr.
Book Value per Share
₹712.4
P/E Ratio
29.37
Higher than its 5-year historical median
Industry PE
52
Price to Book (P/B)
2.15
Higher than its 5-year historical median
Price to Sales (P/S)
1.43
Higher than its 5-year historical median
EV/EBITDA
12.97
Higher than its 5-year historical median
Dividend Yield
0.1%
Profitability Efficiency
Return on Equity (ROE)
8.68%
In line with industry median
Return on Capital Employed (ROCE)
10.53%
In line with industry median
Return on Assets (ROA)
4.14%
Operating Profit Margin
13.4%
Net Profit Margin
5.33%
Gross Profit Margin
10.7%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-9.71%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-0.71%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-4.97%
Asset Quality
Promoter Holding
72.11%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹212 Cr.
Equity
₹3 Cr.
Face Value
₹10
All Time Low / High
₹134.85 / 1778.35

Haleos Labs stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

Quality

Not Good
Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Semi Strong
Check Price chart
Q.1 Is Haleos Labs Ltd a good quality company?
Haleos Labs Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Haleos Labs Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Haleos Labs Ltd vs industry peers?
Haleos Labs Ltd revenue CAGR is 4.68%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Haleos Labs Ltd?
Promoters hold 72.11% of the Haleos Labs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Haleos Labs Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of 12.89% based on the current price.
View More

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Haleos Labs Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % ⓘ45.7%9.5%21.8%11.7%14.4%19.7%10.2%10.9%14%10.7%-
Value Creation
Index ⓘ		2.3-0.30.6-0.20.00.4-0.3-0.20-0.2-

Growth Parameters ⓘ
Sales ⓘ216213344257260346315300333301290
Sales YoY Gr.--1.3%61.6%-25.4%1.3%32.8%-8.8%-4.8%11.1%-9.7%-
Adj EPS ⓘ12,173.416.450.727.141.45237.538.86758.352.5
YoY Gr.--99.9%209.7%-46.5%52.6%25.7%-27.8%3.5%72.7%-13%-
BVPS (₹) ⓘ81,838.7292.4347.2374.6417.9500.2542.6582.9652.2709.7720.5
Adj Net
Profit ⓘ		12.2515.38.212.515.711.411.720.317.616
Cash Flow from Ops. ⓘ19.7827.31421.6-14.74.614.82838.4-
Debt/CF from Ops. ⓘ1.33.41.73.52.1-4.118.662.82.4-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘ3.8%3%-1.5%-9.7%
Adj EPS ⓘ-44.8%7.1%15.8%-13%
BVPSⓘ-41%11.2%9.4%8.8%
Share Price - 12.9% 43.9% 38.9%

Key Financial Parameters ⓘ

Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity % ⓘ		29.85.815.87.510.511.37.26.910.98.67.3
Op. Profit
Mgn % ⓘ		13.26.29.59.311.59.18.411.513.313.513.2
Net Profit
Mgn % ⓘ		5.62.34.53.24.84.63.63.96.15.95.5
Debt to
Equity ⓘ		0.30.30.50.40.40.40.50.50.40.4-
Working Cap
Days ⓘ		85158114159155150182199185206112
Cash Conv.
Cycle ⓘ		1337192328244668626632

Valuation of Haleos Labs - Consolidated

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Sales378261266350316306345334
Operating Expenses ⓘ + 343235235316287275300289
Manufacturing Costs5141516657597070
Material Costs256158137195171151151139
Employee Cost 2327314043525662
Other Costs ⓘ 1310171514132318
Operating Profit ⓘ 3525303529314545
Operating Profit Margin (%) 9.2%9.7%11.4%9.9%9.1%10.2%13.1%13.4%
Other Income ⓘ + 32223452
Exceptional Items ⓘ 000132000
Interest ⓘ 655671097
Depreciation ⓘ 6881011151515
Profit Before Tax ⓘ 2515203317102625
Tax ⓘ 84675477
Profit After Tax 181014251161918
PAT Margin (%) 4.7%3.9%5.1%7.2%3.6%2.1%5.4%5.3%
Adjusted EPS (₹)59.033.744.883.837.930.166.557.3
Dividend Payout Ratio (%)2.50%0%3.40%1.80%4%5%2.30%2.60%
PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 106116129152169177197214
Share Capital ⓘ 3.023.023.023.023.023.023.023.02
Reserves ⓘ 103113126149166174194211
Debt +4058596785806995
Long Term Debt2737394055331850
Short Term Debt1321202730475045
Minority Interest0001320171516
Trade Payables9849677860595361
Others Liabilities ⓘ 3233515465626574
Total Liabilities ⓘ 276256307364398395399460

Fixed Assets

Net Fixed Assets ⓘ +117124130142228223232268
Gross Block136150164177281290312363
Accumulated Depreciation1825343552668095
CWIP ⓘ 316385116010
Investments ⓘ 00000000
Inventories8164628586816780
Trade Receivables4122343446516961
Cash Equivalents 381144122
Others Assets ⓘ 3122324832312938
Total Assets ⓘ 276256307364398395399460
PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + 301535-1115243437
PBT ⓘ 2515202014102625
Adjustment ⓘ 911101416212518
Changes in Working Capital ⓘ 2-810-38-12-4-81
Tax Paid ⓘ -7-3-5-8-3-3-9-7
Cash Flow From Investing Activity ⓘ + -44-27-26-7-31-18-15-58
Capex -24-23-29-42-43-21-15-58
Net Investments -20-4334112-0-0
Others ⓘ 00000000
Cash Flow From Financing Activity ⓘ + 1512-31117-7-1921
Net Proceeds from Shares ⓘ 00000000
Net Proceeds from Borrowing ⓘ 1381420-14-1731
Interest Paid ⓘ -2-3-3-4-4-6-4-2
Dividend Paid ⓘ -1-10-0-0-0-0-0
Others ⓘ 68-1101143-6
Net Cash Flow ⓘ 1-06-80-1-01
PARTICULARSMar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)16.799.1711.0717.987.093.6610.038.68
ROCE (%)20.1411.9112.9618.429.457.4212.610.53
Asset Turnover Ratio1.511.091.051.160.940.850.970.89
PAT to CFO Conversion(x)1.671.52.5-0.441.3641.792.06
Working Capital Days
Receivable Days36.2039.5034.5031.9040.7052.4056.7062.40
Inventory Days71.1091.4077.9068.8087.2090.1070.1070.60
Payable Days139.70169.90154.60135.90146.50143.40135.80151.10

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Haleos Labs Ltd FAQs

The current trading price of Haleos Labs on 16-Oct-2026 16:59 is ₹1,535.2.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 15-Oct-2026 the market cap of Haleos Labs stood at ₹464.1 Cr

The latest P/E ratio of Haleos Labs as of 15-Oct-2026 is 29.27.

The latest P/B ratio of Haleos Labs as of 15-Oct-2026 is 2.13.

The 52-week high of Haleos Labs is ₹1,778.4 and the 52-week low is ₹1,100.6.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Haleos Labs is ₹290 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Haleos Labs Ltd is a below average quality company.

The key valuation ratios of Haleos Labs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Haleos Labs Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Haleos Labs Ltd

No data to display
You have 41 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now